UBS Group’s Acorda Therapeutics ACOR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2024
Q2 | – | Sell |
-106
| Closed | -$1.4K | – | 10479 |
|
|
2024
Q1 | $1.4K | Sell |
106
-192
| -64% | -$2.79K | ﹤0.01% | 8142 |
|
|
2023
Q4 | $4.5K | Buy |
298
+164
| +122% | +$1.86K | ﹤0.01% | 7855 |
|
|
2023
Q3 | $2.01K | Buy |
+134
| New | +$2.02K | ﹤0.01% | 7786 |
|
|
2023
Q2 | – | Sell |
-301
| Closed | -$3.53K | – | 10302 |
|
|
2023
Q1 | $3.53K | Sell |
301
-364
| -55% | -$6.05K | ﹤0.01% | 8308 |
|
|
2022
Q4 | $10.2K | Buy |
665
+62
| +10% | +$723 | ﹤0.01% | 8551 |
|
|
2022
Q3 | $4K | Sell |
603
-832
| -58% | -$6.96K | ﹤0.01% | 9464 |
|
|
2022
Q2 | $13K | Buy |
1,435
+1,294
| +918% | +$23K | ﹤0.01% | 7599 |
|
|
2022
Q1 | $4K | Buy |
141
+140
| +14,000% | +$5.51K | ﹤0.01% | 9376 |
|
|
2021
Q4 | $0 | Sell |
1
-223
| -100% | -$15.4K | ﹤0.01% | 11017 |
|
|
2021
Q3 | $20K | Buy |
224
+221
| +7,367% | +$18.3K | ﹤0.01% | 7181 |
|
|
2021
Q2 | $0 | Hold |
3
| – | – | ﹤0.01% | 10041 |
|
|
2021
Q1 | $0 | Sell |
3
-137
| -98% | -$16.8K | ﹤0.01% | 9678 |
|
|
2020
Q4 | $12K | Sell |
140
-354
| -72% | -$32.5K | ﹤0.01% | 7371 |
|
|
2020
Q3 | $31K | Sell |
494
-89
| -15% | -$6.71K | ﹤0.01% | 5979 |
|
|
2020
Q2 | $51K | Buy |
583
+58
| +11% | +$6.13K | ﹤0.01% | 5844 |
|
|
2020
Q1 | $59K | Buy |
525
+28
| +6% | +$5.51K | ﹤0.01% | 5697 |
|
|
2019
Q4 | $122K | Buy |
497
+233
| +88% | +$58.8K | ﹤0.01% | 5900 |
|
|
2019
Q3 | $91K | Buy |
264
+82
| +45% | +$44.6K | ﹤0.01% | 5818 |
|
|
2019
Q2 | $168K | Sell |
182
-374
| -67% | -$460K | ﹤0.01% | 5028 |
|
|
2019
Q1 | $887K | Sell |
556
-755
| -58% | -$1.36M | ﹤0.01% | 3675 |
|
|
2018
Q4 | $2.45M | Buy |
1,311
+1,069
| +442% | +$2.33M | ﹤0.01% | 2841 |
|
|
2018
Q3 | $571K | Buy |
242
+201
| +490% | +$622K | ﹤0.01% | 4319 |
|
|
2018
Q2 | $142K | Sell |
41
-840
| -95% | -$2.57M | ﹤0.01% | 5193 |
|
|
2018
Q1 | $2.5M | Buy |
881
+178
| +25% | +$533K | ﹤0.01% | 2950 |
|
|
2017
Q4 | $1.81M | Buy |
703
+31
| +5% | +$88.1K | ﹤0.01% | 3273 |
|
|
2017
Q3 | $1.91M | Buy |
672
+358
| +114% | +$943K | ﹤0.01% | 3169 |
|
|
2017
Q2 | $742K | Buy |
314
+194
| +162% | +$384K | ﹤0.01% | 3846 |
|
|
2017
Q1 | $303K | Sell |
120
-242
| -67% | -$697K | ﹤0.01% | 4383 |
|
|
2016
Q4 | $818K | Buy |
362
+188
| +108% | +$447K | ﹤0.01% | 3722 |
|
|
2016
Q3 | $435K | Buy |
174
+69
| +66% | +$206K | ﹤0.01% | 4006 |
|
|
2016
Q2 | $322K | Buy |
105
+10
| +11% | +$32.5K | ﹤0.01% | 4220 |
|
|
2016
Q1 | $302K | Sell |
95
-251
| -73% | -$1.04M | ﹤0.01% | 4181 |
|
|
2015
Q4 | $1.78M | Sell |
346
-314
| -48% | -$1.37M | ﹤0.01% | 2895 |
|
|
2015
Q3 | $2.1M | Sell |
660
-135
| -17% | -$524K | ﹤0.01% | 2693 |
|
|
2015
Q2 | $3.18M | Sell |
795
-62
| -7% | -$239K | ﹤0.01% | 2531 |
|
|
2015
Q1 | $3.42M | Sell |
857
-716
| -46% | -$3.28M | ﹤0.01% | 2416 |
|
|
2014
Q4 | $7.71M | Buy |
+1,573
| New | +$6.75M | 0.01% | 1711 |
|
Other funds holding ACOR
UBS Group's ACOR Position: Q2 2024 in Review
UBS Group sold out of Acorda Therapeutics (ACOR) in Q2 2024, closing a stake of 106 shares — an estimated $1.4K sold.
UBS Group first reported a position in ACOR in Q4 2014 and held it in 37 quarters. The position peaked at $7.71M in Q4 2014. 2 funds tracked by Wall St. Rank hold ACOR as of Q2 2024.
- UBS Group reported no remaining Acorda Therapeutics position as of Q2 2024 after selling out during the quarter.
- UBS Group sold 106 Acorda Therapeutics shares in Q2 2024, an estimated $1.4K.
- UBS Group first reported a position in Acorda Therapeutics in Q4 2014 and held it in 37 quarters.
- UBS Group's Acorda Therapeutics position peaked at $7.71M in Q4 2014.
- 2 funds tracked by Wall St. Rank held Acorda Therapeutics as of Q2 2024.
Based on UBS Group's 13F filing for Q2 2024, filed 14 Aug 2024.